Skye Bioscience, Inc. (SKYE)
SKYE moved a median of -0.36% 30 minutes after news, and -0.58% by the close. How SKYE actually reacts to news — the realized, point-in-time move the market made, measured across 844 labeled events over the last three years with zero look-ahead.
SKYE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 52% | 812 |
| 30-min | -0.36% | 39% | 836 |
| 60-min | -0.77% | 36% | 836 |
| to close | -0.58% | 40% | 837 |
| Middle 50% of SKYE reactions | -1.81% to +1.39% |
|---|---|
| Median reaction (30-min) | -0.36% |
| Measured reactions | 844 |
Half of all Skye Bioscience, Inc. news events land between -1.81% and +1.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SKYE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 27 | -0.39% | 48% | +0.62% |
| Rating reiterations | 24 | +0.04% | 50% | +0.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SKYE ranks against every other measured name →
That’s how SKYE usually reacts — get an email when it moves on news →Email me when SKYE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SKYE's baseline. Nothing else.
Recent SKYE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Skye Bioscience, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.45% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -2.45% | |
| Form 8-K Skye Bioscience, Inc. For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -4.05% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.03% | -4.05% | |
| Form 8-K/A Skye Bioscience, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +7.26% | -7.46% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +7.26% | -7.46% | |
| Form 8-K Skye Bioscience, Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | -10.29% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.64% | -10.29% | |
| Form 10-Q Skye Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -17.44% | -41.69% | |
| Form 8-K Skye Bioscience, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -17.44% | -41.69% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.85% | +4.26% | |
| Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings | Press release | GlobeNewswire | -17.44% | -41.69% | |
| Form 8-K Skye Bioscience, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | +0.00% | |
| Form 8-K Skye Bioscience, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.99% | |
| Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 | Press release | GlobeNewswire | -2.55% | -0.08% | |
| Form 8-K Skye Bioscience, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | -3.87% | |
| UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +0.01% | -1.77% | |
| Form 10-Q Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.47% | -9.61% | |
| Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | -5.47% | -9.61% | |
| Form ARS Skye Bioscience, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.73% | -5.54% | |
| Form DEF 14A Skye Bioscience, Inc. For: May 26 | SEC filing · Form DEF | SEC EDGAR | +0.73% | -5.54% | |
| Form DEFA14A Skye Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.73% | -5.54% | |
| Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit | Press release | GlobeNewswire | +3.87% | +0.86% | |
| Form 8-K/A Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.86% | |
| Form PRE 14A Skye Bioscience, Inc. For: Apr 06 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.86% | |
| Form PREM14A Skye Bioscience, Inc. For: Apr 06 | SEC filing · Form PREM14A | SEC EDGAR | +0.00% | +0.86% | |
| Form 8-K Skye Bioscience, Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | +2.06% | |
| Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development | Press release | GlobeNewswire | -0.92% | +6.40% | |
| Form 8-K Skye Bioscience, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -1.67% | |
| Form S-8 Skye Bioscience, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.49% | +9.29% | |
| Form 10-K Skye Bioscience, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.49% | +9.29% | |
| Form 8-K Skye Bioscience, Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | +9.29% | |
| Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.49% | +9.29% | |
| Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 | Press release | GlobeNewswire | +0.00% | -0.27% | |
| Form 8-K Skye Bioscience, Inc. For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -0.77% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.55% | +0.78% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +2.50% | +4.08% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | — | -2.57% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.17% | -2.83% | |
| Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +2.10% | -3.67% | |
| Form 8-K Skye Bioscience, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -7.92% | |
| Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide | Press release | GlobeNewswire | -1.14% | -7.92% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.14% | -7.92% | |
| Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference | Press release | GlobeNewswire | +2.99% | -4.00% | |
| Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +1.25% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | +2.88% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +2.00% | +2.00% | |
| Skye Bioscience to Present Poster at Keystone Obesity Conference | Press release | GlobeNewswire | +0.01% | +1.09% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Skye Bioscience, Inc. (SKYE) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -1.98% | -3.67% | |
| Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE | Press release | PR Newswire | -1.73% | -1.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SKYE section they belong to.
Where else SKYE is measured.
SKYE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Skye Bioscience, Inc.'s median reaction calculated?
Every labeled SKYE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 844 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of SKYE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SKYE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.